Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Media Releases

Cytotoxic Therapy;  Skin Cancers

New Data on Combination Treatments for Melanoma

Vemurafenib + cobimetinib achieves significant progression-free survival and response rates in melanoma. Phase III trial data shows better outcomes with combination therapy than vemurafenib alone.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.